Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

Inclusion Criteria: * Written informed consent obtained prior to performing screening evaluations. * Male or female, 18 yrs or older. * Diagnosis of type 1 diabetes made 5 years prior to screening visit. * A1C \> 6.0% and 9.0% at screening visit. * Body Mass Index (BMI) 35 kg/m2 at screening visit. * Documented undetectable C-Peptide * Ability to follow instructions for Continuous Glucose Monitoring System (CGMS). * Multiple daily injection participants on at least 3 injections per day. May be treated with NPH or glargine. Exclusion Criteria: * Pregnant or lactating females, or females planning to become pregnant during the study or not using an acceptable method of contraception. Females of childbearing potential must have a negative pregnancy test at Visit 3 and Visit 5. Females who become pregnant during the study will be discontinued. * Type 2 diabetes. * Two or more severe hypoglycemic episodes (requiring assistance) within six months of Screening. * Drugs known to affect glycemia (eg. steroids, beta blockers) or conditions that are likely to require steroid therapy or cause metabolic instability in the next 6 months. * History of allergy or intolerance to NPH or glargine. * History of hypoglycemia unawareness i.e. no warning symptoms accompanying low (\<50 mg/dl) blood glucose levels. * Unable and/or unlikely to comprehend and/or follow the study protocol (including self blood glucose monitoring, CGMS). * Currently using an insulin pump. * Pituitary disorder (Acromeg…